We only have this paper's title and publication details.
Read it at the sourceAnswers are grounded in this paper and cite their sources.
Open label study evaluates vimseltinib's effect on chronic graft-versus-host disease after therapy failure, suggesting new treatments may be needed.
No takes yet. Share an insight, caveat, or question.
Bejanyan et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: